Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec.

The Health Management Academy's executive forum recognized alongside ASCO, AACR, and other leading gatherings in ...

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel ...

An updated edition of the February 5, 2026, article. The global oncology market is entering a period of rapid evolution, ...

START will leverage Trialing’s platform to distribute curated information on ongoing early-phase oncology trials.

The future of precision medicine will depend less on choosing between genomics or real-world evidence and more on how ...

As hospitals reduced their spending on oncology treatments due to the increasing availability of biosimilars, the ...

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred ...

Safety and QoL considerations are reshaping sequencing, including avoidance of immunotherapy in certain drivers and adoption ...

CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, ...

Coherus Oncology (CHRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...